Nivalis Therapeutics,Inc. (NASDAQ:NVLS) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition
On February 13, 2017, Nivalis Therapeutics,Inc. issued a press
release announcing its financial results for the quarterand year
ended December 31, 2016.A copy of the press release is attached
as Exhibit99.1 and is incorporated herein by reference.
The information in this Current Report on Form8-K, including the
information incorporated by reference herein and Exhibit99.1
attached hereto, shall not be deemed to be filed for purposes of
Section18 of the Securities Exchange Act of 1934 (the Exchange
Act) or otherwise subject to the liabilities of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.
Item 9.01Financial Statements and Exhibits.
(d)Exhibits.
Number and Description
|
99.1 |
Press Release, dated February13, 2017. |
2
About Nivalis Therapeutics, Inc. (NASDAQ:NVLS)
Nivalis Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. It operates through discovering and development of potential drugs segment. Its operations are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. Its product candidate, N91115, is a small molecule compound that addresses a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) resulting from mutations in the CFTR gene, the underlying cause of CF. The Company is conducting a Phase II clinical trial designed to demonstrate the safety of a triple therapy of N91115 along with lumacaftor/ivacaftor in over 130 adult CF patients homozygous for F508del. Nivalis Therapeutics, Inc. (NASDAQ:NVLS) Recent Trading Information
Nivalis Therapeutics, Inc. (NASDAQ:NVLS) closed its last trading session down -0.02 at 2.37 with 475,720 shares trading hands.
